Chai Discovery
#3 en IA conversationnelle & ChatbotsChai Discovery · 4× · vu le 12 août 2026
71
Momentum
Chai Discovery is an AI company founded in San Francisco in 2024 that develops generative models for predicting and designing biomolecules—particularly antibodies. It is NOT a classical conversational chatbot, but rather an AI platform for drug and antibody design in pharmaceutical research. The flagship model Chai-1 (September 2024) is Open Source for structure prediction; Chai-2 (2025) enables de novo antibody design through Zero-Shot generation; Chai-3 is the current commercial version, which has been licensed to Eli Lilly, Pfizer, and Novartis, among others. The company is backed by OpenAI, among others, and reached a valuation of $3.8 billion USD in July 2026 following Series C funding.
Historique du momentum
14.05.12.08.
Fonctionnalités
| Autonomy Level | Zero-shot generative design: model autonomously generates antibody candidates from target structure/epitope without prior examples |
| Channels | Web platform (chaidiscovery.com), API/early access for pharma partners, open-source repository on GitHub/Hugging Face |
| License | Chai-1: Apache 2.0 license (code and model weights), usable for both commercial and academic purposes |
| Modalities | Multimodal: proteins, small molecules (SMILES), DNA, RNA, glycosylations, antibody-antigen interactions |
| Platform | Web-hosted tool and Python package (chai_lab, pip install) for Linux with GPU (CUDA); accessible via chaidiscovery.com and GitHub |
| Price | Chai-1 free (open source); Chai-2/Chai-3 available only via early-access/enterprise licensing to partner companies, no public price |
| Release Date | Chai-1 released September 9, 2024 |
